Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity

NCT07382752 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT07382752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07382752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity
Lead sponsor
M.D. Anderson Cancer Center
Phase
Observational
Overall status
Recruiting
Start date
January 9, 2026
Completion date
June 30, 2030
Enrollment
1,200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular, tumor